The downregulation of TCF7L1 in BLCA tissues contributes to diminished HSPB6 expression, suggesting that enhancing TCF7L1 activity could serve as a strategic avenue for upregulating HSPB6, thereby potentially inhibiting cancer progression. This evidence concerns the gene HSPB6 and cancer.